Behavioural effects of genetically engineered cells releasing dopa and dopamine after intracerebral grafting in a rat model of Parkinson's disease
- PMID: 1687823
Behavioural effects of genetically engineered cells releasing dopa and dopamine after intracerebral grafting in a rat model of Parkinson's disease
Abstract
The relative importance of synaptic versus paracrine dopamine transmission for the occurrence of functional effects following intrastriatal grafting is not fully established. In the present study we grafted cell lines, expressing the form I of human tyrosine hydroxylase after infection with a recombinant retrovirus and selection in tyrosine-free-medium, to the denervated striatum in order to analyse the extent to which extracellular dopamine levels can be restored and the effect of a diffuse release of dopamine on motor impairement in a rat model of Parkinson's disease. In petri dish, the modified fibroblast cells (NIH.3T3) release DOPA constitutively whereas the modified endocrine cells (RIN) store and release dopamine in a regulated way. Interestingly, in denervated striatum, grafts of modified fibroblast cells produce DOPA which was efficiently converted into dopamine by the host striatal tissue. In the grafted striatum, both fibroblast and endocrine cells restore subnormal levels of diffuse release of dopamine which is notably unaffected and stimulated, respectively, by high concentration of potassium, in connection with the in vitro properties of the grafted cells. The intrastriatal grafts of modified cells partially reversed the apomorphine-induced but not the amphetamine-induced motor asymmetry. We discuss the implications of these results in the context of Parkinson disease.
Similar articles
-
Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.Neuroscience. 2006 Aug 11;141(1):521-31. doi: 10.1016/j.neuroscience.2006.03.068. Epub 2006 May 11. Neuroscience. 2006. PMID: 16697115
-
[The changes of striatal dopamine levels in the brain in rat models for Parkinson's disease after gene therapy].Zhonghua Yi Xue Za Zhi. 1996 Jul;76(7):490-2. Zhonghua Yi Xue Za Zhi. 1996. PMID: 9275495 Chinese.
-
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.Exp Neurol. 2004 Jul;188(1):65-73. doi: 10.1016/j.expneurol.2004.03.004. Exp Neurol. 2004. PMID: 15191803 Clinical Trial.
-
Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.Brain Res Rev. 2006 Sep;52(2):244-56. doi: 10.1016/j.brainresrev.2006.03.001. Epub 2006 Apr 27. Brain Res Rev. 2006. PMID: 16644019 Review.
-
Grafted dopamine neurons: Morphology, neurochemistry, and electrophysiology.Prog Neurobiol. 2010 Feb 9;90(2):190-7. doi: 10.1016/j.pneurobio.2009.10.009. Epub 2009 Oct 21. Prog Neurobiol. 2010. PMID: 19853009 Review.
Cited by
-
Maintaining the neuronal phenotype after injury in the adult CNS. Neurotrophic factors, axonal growth substrates, and gene therapy.Mol Neurobiol. 1995 Apr-Jun;10(2-3):151-67. doi: 10.1007/BF02740673. Mol Neurobiol. 1995. PMID: 7576305 Review.
-
Ultrastructural analysis of graft-to-host connections, with special reference to dopamine-neuropeptide Y interactions in the rat striatum, after transplantation of fetal mesencephalon cells.Exp Brain Res. 1994;98(1):84-96. doi: 10.1007/BF00229112. Exp Brain Res. 1994. PMID: 7912201
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical